Uniprogen Biotech Private Limited, a active private limited company, was established on 02 January 2010 in Navi Mumbai, Maharashtra, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U51909MH2010PTC198320. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹1.05 Cr and a paid-up capital of ₹1.01 Cr.
It upholds a compliant status. Employing 3 professional, Its leadership includes Santanu Nayak (Director), Anandkumar Bhanupratap Singh (Director), Priyajit Chakraborty (Additional Director). Past directors included Bablu Ramchandra Gupta, Shailendra Paltan Jaiswal, Soundarrajan Santhanaraman. Its latest AGM occurred on 30 November 2021, with the balance sheet filed on 31 March 2021. It is based at Shop No 16, Ashapura Chs Plot No 51, Sec 19, Airoli, Navi Mumbai, Maharashtra, 400708.
U51909MH2010PTC198320
198320
02 January 2010
₹1.05 Cr
₹1.01 Cr
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Uniprogen Biotech Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Santanu Nayak | Director | 15 Jan 2010 | Current |
| Anandkumar Bhanupratap Singh | Director | 15 Jan 2010 | Current |
| Priyajit Chakraborty | Additional Director | 19 Mar 2020 | Current |
| Boomi Nathan Shankar | Director | 02 Jan 2010 | Current |
| Madhu Mehta | Director | 01 Apr 2013 | Current |
| Nilesh Rampratap Chaubey | Director | 03 Aug 2018 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 25 Apr 2019 | Past |
| Pramod Abcsdd | Director | 29 Jul 2015 | Past |
| Pramod Abcsdd | Director | 25 Apr 2019 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2014 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2018 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Uniprogen Biotech Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 30.19% decrease. The company also saw a substantial improvement in profitability, with a 78.85% increase in profit. The company's net worth dipped by a decrease of 8.83%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2021, Uniprogen Biotech had a promoter holding of 98.50% and a public holding of 1.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Uniprogen Biotech has a workforce of 3 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Uniprogen Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Uniprogen Biotech's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Uniprogen Biotech Private Limited last Annual general meeting of members was held on 30 Nov 2021 as per latest MCA records. was documented.
The activity Uniprogen Biotech Private Limited has filed its annual Financial statements for the year ended 31 Mar 2021 with Roc Mumbai. was completed.
The activity Priyajit Chakraborty was appointed as a Additional Director was appointed as a Additional Director on 19 Mar 2020 & has been associated with this company since 5 years 8 months . was completed.
The activity Nilesh Rampratap Chaubey was appointed as a Director was appointed as a Director on 03 Aug 2018 & has been associated with this company since 7 years 4 months . was completed.
Progress on Madhu Mehta was appointed as a Director was appointed as a Director on 01 Apr 2013 & has been associated with this company since 12 years 8 months . was documented.
The activity Santanu Nayak was appointed as a Director was appointed as a Director on 15 Jan 2010 & has been associated with this company since 15 years 10 months . was completed.
The CIN of Uniprogen Biotech Private Limited is U51909MH2010PTC198320.
Uniprogen Biotech Private Limited is headquartered at Shop No 16, Ashapura Chs Plot No 51, Sec 19, Airoli, Navi Mumbai, Maharashtra, 400708.
Uniprogen Biotech Private Limited was incorporated on 02 January 2010.
The current directors of Uniprogen Biotech Private Limited are
The primary industry of Uniprogen Biotech Private Limited is Trade.
Uniprogen Biotech Private Limited is unlisted.
The authorized capital of Uniprogen Biotech Private Limited is ₹1.05 Cr, and the paid-up capital is ₹1.01 Cr.
The compliance status of Uniprogen Biotech Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX